The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC.
Journal of hepatocellular carcinoma（2023）
摘要
In patients with advanced HCC, TACE-TKIs-C may improve overall and progression-free survival outcomes over TACE-TKIs with manageable safety profile.
更多查看译文
关键词
camrelizumab,hepatocellular carcinoma,propensity score matching,transarterial chemoembolization,tyrosine kinase inhibitors
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要